上海惠永药物研究

Shanghai Huiyong Medicine Research, also known as Huiyong Pharma, is a specialized biopharmaceutical company focused on the development of high-end complex formulations and advanced drug delivery systems. Founded in 2018 and based in Shanghai's Zhangjiang Hi-Tech Park, the company leverages proprietary platforms in microspheres, liposomes, and nanocrystals to improve the therapeutic profile of established drugs. Their research strategy primarily targets the 505(b)(2) regulatory pathway, focusing on therapeutic areas such as the central nervous system, oncology, and metabolic diseases. Huiyong Pharma's pipeline includes long-acting injectables and targeted delivery systems designed to enhance patient compliance and reduce side effects. The company operates integrated R&D facilities and GMP-compliant pilot production lines to support its internal programs and external collaborations.